SG11202110406SA - Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole - Google Patents

Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole

Info

Publication number
SG11202110406SA
SG11202110406SA SG11202110406SA SG11202110406SA SG11202110406SA SG 11202110406S A SG11202110406S A SG 11202110406SA SG 11202110406S A SG11202110406S A SG 11202110406SA SG 11202110406S A SG11202110406S A SG 11202110406SA SG 11202110406S A SG11202110406S A SG 11202110406SA
Authority
SG
Singapore
Prior art keywords
pyrazole
thienyl
vinyl
solid forms
solid
Prior art date
Application number
SG11202110406SA
Other languages
English (en)
Inventor
An-Hu Li
Satish Kumar Sakilam
Dong Sung Lim
Original Assignee
Angion Biomedica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angion Biomedica Corp filed Critical Angion Biomedica Corp
Publication of SG11202110406SA publication Critical patent/SG11202110406SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202110406SA 2019-04-11 2020-04-10 Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole SG11202110406SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832519P 2019-04-11 2019-04-11
PCT/US2020/027710 WO2020210657A1 (en) 2019-04-11 2020-04-10 Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole

Publications (1)

Publication Number Publication Date
SG11202110406SA true SG11202110406SA (en) 2021-10-28

Family

ID=72751396

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110406SA SG11202110406SA (en) 2019-04-11 2020-04-10 Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole

Country Status (13)

Country Link
US (2) US10875849B2 (pt)
EP (1) EP3927702A4 (pt)
JP (1) JP2022526827A (pt)
KR (1) KR20220004083A (pt)
CN (1) CN114026085A (pt)
AU (1) AU2020272036A1 (pt)
BR (1) BR112021020367A2 (pt)
CA (1) CA3133803A1 (pt)
EA (1) EA202192786A1 (pt)
IL (1) IL287118A (pt)
MX (1) MX2021012250A (pt)
SG (1) SG11202110406SA (pt)
WO (1) WO2020210657A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020272036A1 (en) 2019-04-11 2021-11-04 Angion Biomedica Corp. Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole
US20230000828A1 (en) * 2019-10-31 2023-01-05 Angion Biomedica Corp. Improving renal function after kidney transplantation
US11358963B2 (en) 2020-03-05 2022-06-14 Ankh Life Sciences Limited Low-temperature synthesis of thymoquinone and harmaline compounds
EP4228626A2 (en) * 2020-10-14 2023-08-23 Angion Biomedica Corp. Preparation of terevalefim and formulations thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE138770C (pt)
JPS48713Y1 (pt) 1967-12-19 1973-01-09
US4806535A (en) 1987-07-22 1989-02-21 Rorer Pharmaceutical Corporation Imidazolylphenyl and 1,2,4-triazolylphenyl benzopyridazinone and pyridopyridazinone compounds and their use for increasing cardiatonic contractility
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH02193994A (ja) 1989-01-23 1990-07-31 Kyowa Hakko Kogyo Co Ltd ピリダジノン誘導体
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
FR2669633B1 (fr) 1990-11-23 1993-01-22 Adir Nouveaux derives de la benzoselenazolinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE4405428A1 (de) 1993-07-05 1995-03-30 Bayer Ag 2-Oximino-2-thienyl-essigsäurederivate
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
JP3818322B2 (ja) 1994-04-28 2006-09-06 敏一 中村 コラーゲン分解促進剤
KR100725199B1 (ko) 1995-08-29 2007-08-16 안제스에무지 가부시키가이샤 에이치지에프유전자를함유하는약제
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
ES2212814T3 (es) 1996-10-31 2004-08-01 Harbor Branch Oceanographic Institution, Inc. Uso de compuestos y composiciones antiinflamatorias neurogenicas.
JPH11288112A (ja) 1998-04-06 1999-10-19 Mitsubishi Paper Mills Ltd 電子写真感光体
KR20010101675A (ko) 1999-01-26 2001-11-14 우에노 도시오 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6437006B1 (en) 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
US7459536B1 (en) 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
AU2001259063A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002002593A2 (en) 2000-06-29 2002-01-10 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
DE10047486A1 (de) 2000-09-26 2002-04-11 Bayer Ag Phenoxyphenyl Alkansulfonate
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US6589997B2 (en) 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
US6610726B2 (en) 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
US20030073692A1 (en) 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
DE10157184A1 (de) 2001-11-22 2003-07-17 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von Vinylarenen, -heteroarenen und 1,3-Dienen aus Aryl-, bzw. Heteroaryl-bzw. Vinylcarbonsäurederivaten
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
AR038535A1 (es) 2002-02-22 2005-01-19 Schering Corp Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos
AU2002313690A1 (en) 2002-07-19 2004-02-09 Targacept, Inc. Five-membered heteroaromatic olefinic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of ncotinic cholinergic receptors
US7192976B2 (en) 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
EP1799651A2 (en) 2004-09-28 2007-06-27 Angion Biomedica Corp. Small molecule modulators of cytokine activity
WO2006060654A2 (en) 2004-12-01 2006-06-08 Divergence, Inc. Pesticidal compositions and methods
WO2006078941A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
US20110230407A1 (en) 2005-03-14 2011-09-22 Alexander Yuzhakov Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
US7879898B1 (en) 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
CN101501029A (zh) * 2006-08-04 2009-08-05 安斯芙制药公司 N-(2-乙酰基-4,6-二甲基苯基)-3-{[(3,4-二甲基-5-异噁唑基)-氨基]磺酰}-2-噻吩酰胺的多晶型物
DK2134691T3 (da) 2007-03-08 2012-05-07 Janssen Pharmaceutica Nv Quinolinonderivativer som parp- og tank-inhibitorer
EP2170911B1 (en) 2007-06-22 2018-11-28 UDC Ireland Limited Light emitting cu(i) complexes
US8193177B2 (en) 2007-11-13 2012-06-05 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases
CN102149379A (zh) 2008-07-10 2011-08-10 安吉翁生物医药有限公司 调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物
US20110098304A1 (en) 2008-10-22 2011-04-28 Bijoy Panicker Small molecule inhibitors of PARP activity
WO2010068287A2 (en) 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2011019400A2 (en) 2009-08-12 2011-02-17 Angion Biomedica Corp. Enhancement of cellular transplantation using small molecule modulators hepatocyte growth factor (scatter factor) activity
EP2550260A1 (en) 2010-03-24 2013-01-30 Medical University Of South Carolina Compositions and methods for the treatment of degenerative diseases
CA2829790C (en) 2010-03-30 2018-06-05 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
TWI492949B (zh) * 2010-06-09 2015-07-21 Abbvie Bahamas Ltd 結晶型激酶抑制劑
AU2011312333A1 (en) 2010-10-05 2013-05-02 Angion Biomedica Corp. Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2012058531A2 (en) 2010-10-29 2012-05-03 North Carolina State University Modulation of response regulators by imidazole derivatives
WO2013108105A2 (en) * 2012-01-18 2013-07-25 Aurobindo Pharma Limited Novel solvates of darunavir
EP2757106A1 (de) 2013-01-21 2014-07-23 Saltigo GmbH Substituierte Benzimidazolyphosphin-Verbindungen sowie ein Verfahren zur decarboxylierenden Kohlenstoff-Kohlenstoff-Verknüpfung
MX2015012867A (es) 2013-03-15 2016-06-10 Verseon Corp Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
AU2014238478B2 (en) 2013-03-15 2018-07-19 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
AU2020272036A1 (en) 2019-04-11 2021-11-04 Angion Biomedica Corp. Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole
US20230000828A1 (en) * 2019-10-31 2023-01-05 Angion Biomedica Corp. Improving renal function after kidney transplantation

Also Published As

Publication number Publication date
AU2020272036A1 (en) 2021-11-04
KR20220004083A (ko) 2022-01-11
US11370783B2 (en) 2022-06-28
WO2020210657A1 (en) 2020-10-15
BR112021020367A2 (pt) 2021-12-07
EA202192786A1 (ru) 2022-01-11
US20210078984A1 (en) 2021-03-18
EP3927702A4 (en) 2022-05-11
US10875849B2 (en) 2020-12-29
CA3133803A1 (en) 2020-10-15
EP3927702A1 (en) 2021-12-29
CN114026085A (zh) 2022-02-08
IL287118A (en) 2021-12-01
JP2022526827A (ja) 2022-05-26
MX2021012250A (es) 2022-01-18
US20200369654A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
IL287118A (en) Solid forms of (e)-3-[2-(2-thianyl)vinyl]-1h-pyrazole
IL283333A (en) Heterocyclic compounds
HK1263336A1 (zh) 含有1-(3-(2-(1-苯並噻吩-5-基-)乙氧基)丙基)氮雜環丁-3-醇或其鹽的片劑
PT3814341T (pt) Inibidores de recetor erbb
EP3743595A4 (en) OPTIMIZATION OF THE PENETRATION RATE
IL289617A (en) Heterocyclic compounds
IL289595A (en) Heterocyclic compounds
EP3574447A4 (en) IMAGE COMPENSATION FOR MOTORCYCLE INCLINATION
EP3453225A4 (en) IMPROVED APPLICATION SPECIFIC CONGESTION CONTROL METHOD FOR DATA COMMUNICATION MECHANISM
IL288987A (en) New heterocyclic compounds
IL272992A (en) Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
GB2558898B (en) Controlling transfer of data
NO20190133A1 (en) Fremgangsmåte for inspeksjon av rør
GB201915191D0 (en) Novel heterocyclic compounds
EP3798053A4 (en) CAB OF A CONSTRUCTION MACHINE
GB2578453B8 (en) Software defined networks
EP3744105A4 (en) MULTIMEDIA COMMUNICATION BRIDGE
GB201911969D0 (en) Breakout
PL3560882T3 (pl) Przejście do windy
SG11202110151TA (en) Inter-core network reselection control
GB201803398D0 (en) Methods for controlling gene expression
GB202015084D0 (en) Video application parameter setting platform
EP3980406A4 (en) Heterocyclic compounds
GB2584367B (en) Cavity brick vent
GB202002871D0 (en) Software defined network optimsation